Title variants
Languages of publication
Abstracts
Introduction: Recombinant alpha(1)-proteinase inhibitor, clinically developed for inhalative augmentation therapy in patients with alpha(1)-proteinase inhibitor deficiency or cystic fibrosis, may directly contribute to leukocyte accumulation as it may function as a chemoattractant. The migratory effects of yeast-derived human recombinant alpha(1)-proteinase inhibitor on human peripheral blood neutrophils and eosinophils were therefore tested in vitro. Materials and Methods: Human peripheral blood leukocytes were prepared from forearm venous blood and tested for migration toward various preparations of yeast-derived recombinant alpha(1)-proteinase inhibitor in modified Boyden-chamber micropore filter assays. Results: No direct effects of yeast-derived recombinant human alpha(1)-proteinase inhibitor on in vitro migration of isolated neutrophils or eosinophils were seen. Conclusions: The lack of direct chemotactic effects of recombinant human alpha(1)-proteinase inhibitor despite anti-inflammatory effects in other biological activities of leukocytes may contribute to the preserved antibacterial defense mechanisms observed in patients under experimental augmentation therapy with inhaled alpha(1)-proteinase inhibitor.
Discipline
Publisher
Year
Volume
Issue
Pages
399-403
Physical description
Contributors
References
Document Type
ARTICLE
Publication order reference
Christian J. Wiedermann, Department of Medicine, Central Hospital of Bolzano, L. Bohler Street 5, 39100 Bolzano (BZ), Italy
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-b6cfb89d-ab50-3903-ae25-e7d2579c4406
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.